研究成果

重點成果:

幽門螺旋桿菌陽性的早期胃黏膜相關淋巴組織淋巴瘤之抗生素治療

研究發現幽門螺旋桿菌陽性的早期胃黏膜相關淋巴組織淋巴瘤,可經由單純使用抗生素廓清幽門螺旋桿菌做為第一線治療而治癒。其可提供學術界未來研究胃淋巴瘤致病機轉的另一方向,亦提供患者一個相對於全身性化學治療,便宜、簡易且安全、無副作用的有效治療選項。

化學治療誘發B型肝炎活化之監測與預防

研究發現B型肝炎帶原者罹患非何杰金氏淋巴癌而接受化學治療時,合併使用抗病毒藥物可以有效預防B型肝炎病毒再活化及肝炎復發;進而促成健保署對使用免疫抑制治療的B型肝炎帶原者之癌症病人,同意給予預防性抗病毒藥物治療之健保給付。後續研究發現曾經感染B型肝炎的惡性淋巴癌患者接受含有rituximab之化學治療時,其HBV再活化與B型肝炎復發機率有顯著關連性、且可能與較差的整體存活率有關。未來可用來預測曾經感染B型肝炎的惡性淋巴癌患者之B型肝炎復發機率,篩選出高風險性患者施予抗病毒藥物治療之預防性給藥,以撙節健保資源。

晚期胰、膽癌化學治療處方之開發

研究結果與國外其他化療方式相較,針對無法切除之胰臟癌病患,GOFL48有較高的整體存活率及無病存活率,此療法已成為台灣對無法切除之胰臟癌病患最普遍的化學治療方式。近年來癌研所持續致力於改善癌症治療方法,針對困難癌症發展如SLOG之安全、有效且可負擔的處方,並於TCOG下推展多中心臨床試驗。

肝癌術後輔助性抗病毒治療之隨機分組試驗

研究結果雖然顯示輔助性干擾素治療未能有效降低肝細胞癌術後之復發率,卻發現對選擇性之肝癌病人部分肝臟切除及復發後之多科整合治療,已能有效提高該病患群肝癌之治癒率;此為目前相關研究中最佳試驗成果,足以展現台灣醫者在國際肝癌手術等領域的領導地位。藉由回溯性次群分析,發現手術後接受治療前血清中B型肝炎病毒之基因型及病毒量為B型肝炎病毒相關肝細胞癌病患腫瘤復發之重要預後因子,進而執行肝細胞癌術後輔助性抗B型肝炎病毒藥物治療之臨床試驗,對未來肝細胞癌術後治療指引之建立將提供重要臨床佐證資料。

論文:

  1. T1309 — “Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximabbased concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: final analysis of a phase 2 clinical trial”. Yen CJ, Tsou HH, Hsieh CY, Chu CY, Chiu CF, Chen CC, Tsao CJ, Tsai KY, Tsai ST, Chang JY, Chang KY. Head & Neck. June 2019; 41:1703-1712.
  2. T1303 –“Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study”. Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, Lou PJ, Wang HM, Tsai MH, Lai SC, Liu TW. Ann Oncol. 2018 Sep 1;29(9):1972-1979.
  3. T1408 — “Quantification of HBV Core Antibodies May Help Predict HBV Reactivation in Patients with Lymphoma and Resolved HBV Infection”. Yang HC, Tsou HH, Pei SN, Chang CS, Chen JH, Yao M, Lin SJ, Lin J, Yuan Q, Xia N, Liu TW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. J Hepatol. 2018 Aug; 69(2):286-292.
  4. T3211 — “The Clinical Impact of the Novel Tumor Marker DR-70 in Unresectable Gastric Cancer Patients”. Hung YP, Chen MH, Lin JS, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. J Chin Med Assoc. 2018 Jul; 81(7):593-598.
  5. T1210-”Expression Levels of ROS1/ALK/c-MET and Therapeutic Efficacy of Cetuximab plus Chemotherapy in Advanced Biliary Tract Cancer”. Chiang NJ, Hsu C, Chen JS, Tsou HH, Shen YY, Chao Yee, Chen MH, Yeh TS, Shan YS, Huang SF, Chen LT.  Sci Rep. 2016 May 3; 6:25369.
  6. T3211- “Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial”. Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. AMedicine (Baltimore). 2016 Jan; 95(3):e2565.
  7. T1394-“Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncology”. Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan TC, Huang PY, Benhamou E, Zhu G, Chua TT, Chen Y, Mai HQ, Kwong LW, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui P, Lu TX, Bourhis J, Pignon P, on behalf of the MAC-NPC Collaborative Group. 2015 Jun; 16:645-55.
  8. T1210-“A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer”. Chen JS; Hsu C; Chiang NJ; Tsai CS; Tsou HH; Huang SF; Bai LY; Chang IC; Shiah HS; Ho CL; Yen CJ; Lee KD; Chiu CF; Rau KM; Yu MS; Yang Y; Hsieh RK; Chang JY; Shan YS; Chao Y; Chen LT, on behalf of the TCOG. Annals Oncology. 2015 May; 26(5):943-9.
  9. T1405-“Long-term Results of A Phase II Trial with Frontline Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy for Localized Nasal Natural Killer/T-cell Lymphoma”. Tsai HJ, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, Chiu CF, Chang YF, Chang SM, Chang MC, Su IJ. Eur J Haematol. 2015 Feb; 94(2):130-7.
  10. T1408-“Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients with Resolved HBV Infection: A Prospective Study”. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WY, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL; Taiwan Cooperative Oncology Group. Hepatology. 2014 Jun; 59(6):2092-100.
  11. T2207-“Celecoxib plus Chemoradiotherapy for Locally Advanced Rectal Cancer: A Phase II TCOG Study”. Wang LW, Hsiao CF, Chen WT, Lee HH, Lin TC, Chen HC, Chen HH, Chien CR, Lin TY, Liu TW. J Surg Oncol. 2014 May; 109(6):580-5.
  12. T1297-“Long-term Results of a Randomized, Observation-controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma after Curative Resection”. Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, TCOG, NHRI. Ann Surg. 2012 Jan; 255(1):8-17.
  13. T1309-“A Phase II Study of Neoadjuvant Bio-chemotherapy with Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Head and Neck Cancer – Representative of Head and Neck Cancer Study Group of Taiwan Cooperative Oncology Group”. Chang KY, Yen CJ, Hsieh CY, Tsou HH, Chiu CF, Chen CC, Tsao CJ, Tsai KY, Tsai ST, Chang JY. E ur J Cancer. 2011; 47:S547-S548.
  14. T1204-“Induction chemotherapy with gemcitabine, oxaliplatin, and 5-Fluorouracil/ Leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study”. Ch’ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT. Int J Radiat Oncol Biol Phys. 2011 Dec 1; 81(5):e749-57.
  15. T1401-“A Revisit for Prophylactic Lamivudine for Chemotherapy-associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma: a Randomized Trial”. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL and Chen PJ. Hepatology, 2008 Mar; 47(3):844-53.
  16. T1899 LAB-“Human Papillomaviral Load Changes in Low-grade Squamous Intraepithelial Lesions of the Uterine Cervix”. Ho CM, Cheng WF, Chu TY, Chen CA, Chuang MH, Chang SF, Hsieh CY. Br J Cancer. 2006 Nov 20; 95(10):1384-9.
  17. T1899-“The Distribution and Differential Risks of Human Papillomavirus Genotypes in Cervical Preinvasive Lesions: A Taiwan Cooperative Oncologic Group (TCOG) Study”. Chen CA, Liu CY, Chou HH, Chou CY, Ho CM, Twu NF, Kan YY, Chuang MH, Chu TY, Hsieh CY; Taiwan Cooperative Oncologic Group. Int J Gynecol Cancer. 2006 Sep-Oct; 16(5):1801-8.
  18. T1899-“Epidemiologic Correlates of Cervical Human Papillomavirus Prevalence in Women with Abnormal Pap Smear Tests: A Taiwan Cooperative Oncology Group (TCOG) Study”. Sun CA, Hsiung CA, Lai CH, Chen CA, Chou CY, Ho CM, Twu NF, Feng WL, Chuang MH, Hsieh CY, Chu TY. J Med Virol. 2005 Oct; 77(2):273-81.
  19. T1296-“Long-Term Results of Anti-helicobacter pylori Therapy in Early-stage Gastric High-grade Transformed MALT Lymphoma”. Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu BS, Jan CM, Wang WM, Wang TE, Wu CW, Chen CL, Su IJ, Whang-Peng J, Cheng AL. J Natl Cancer Inst. 2005 Sep 21; 97(18):1345-53.
  20. T1296-“Nuclear Expression of BCL10 or Nuclear Factor Kappa B Helps Predict Helicobacter Pylori-independent Status of Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphomas with or without t(11;18)(q21;q21)”. Yeh KH, Kuo SH, Chen LT, Mao TL, Doong SL, Wu MS, Hsu HC, Tzeng YS, Chen CL, Lin JT, Cheng AL. Blood. 2005 Aug 1; 106(3):1037-41.
  21. T1495-“Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients”. Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. World J Gastroenterol. 2005 Sep 14; 11(34):5283-8.
  22. T1495-“Steroid-Free Chemotherapy Decreases Risk of Hepatitis B Virus (HBV) Reacti­vation in HBV-carriers with Lymphoma”. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J; Lymphoma Committee of TCOG. Hepatology. 2003 Jun; 37(6): 1320-8.
  23. T1394-“A Phase III Study of Adjuvant Chemotherapy in Advanced Nasopharyngeal Carcinoma Patients”. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, Wang LW, Lai YL, Hsu MM, Lian SL, Chang CH, Liu TW, Chin YH, Yen SH, Perng CH, Chen KY. Int J Radiat Oncol Biol Phys. 2002 Apr 1; 52(5):1238-44.
  24. T1188-“Weekly CAF Chemotherapy for Advanced Breast Cancer Patients”. Hwang WS, Hsiung CA, Ko WS, Wang CC, Chang JY, Lai GM, Hsieh RK, Tsao CJ, Chen LT, Law CK, Cheng AL, Fan SF, Tzeng CH, Chiou TJ, Whang-Peng J. Oncology. 1997 Jul-Aug; 54(4):293-7.

[BIG International Trials]

  1. APHINITY- “Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer”. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators (Liu TW). N Engl J Med. 2017 Jul 13; 377(2):122-131.
  2. NeoALTTO-“Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial”. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lancet. 2012 Feb 18; 379(9816):633-40.
  3. HERA - “Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial”. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu TW, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ. J Clin Oncol. 2010 July; 28(21):3422-8.
  4. HERA-“Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer”. Piccart-Gebhart MJ1, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. N Engl J Med. 2005 Oct 20; 353(16):1659-72.
Share Button

Comments are closed.